Hypertrophic cardiomyopathy
A heart muscle condition, usually passed down in families, in which the walls of the heart become thick.1 Some people have no symptoms; others get chest pain, breathlessness, dizziness or fainting, especially during exercise.1 There is usually no cure, but medicines, procedures and devices can control the symptoms and prevent problems.2 It affects about 1 in 500 people, and for most it does not change daily life.2
Read more about Hypertrophic cardiomyopathyTrial-stage treatments and research studies you can join
Filters
- Catheter procedure to slice thickened heart muscle in hypertrophic cardiomyopathy
Tests the SESAME catheter procedure in adults with thickened heart muscle blocking blood flow.
Atlanta, United StatesAlso Boston, Charlottesville, Roanoke, Roslyn, The Bronx, Washington D.C., YorkAge 21 to 100 - BHB-1893 tested against metoprolol for obstructive hypertrophic cardiomyopathy
Tests BHB-1893 against metoprolol in adults with heart thickening causing symptoms.
Burlington, United StatesAlso Manhasset, Plano, Rock HillAge 18 to 85 - Safety of HTX-001 in healthy adults and people with nonobstructive hypertrophic cardiomyopathy
Tests HTX-001 in healthy adults and adults with nonobstructive hypertrophic cardiomyopathy.
Boston, United StatesAlso Cincinnati, Kansas CityAge 18 to 70 - Testing ninerafaxstat against placebo in adults with symptomatic non-obstructive hypertrophic cardiomyopathy
Tests ninerafaxstat against a placebo in adults with symptomatic non-obstructive heart thickening.
Atlanta, United StatesAlso Baltimore, Boston, Burlington, Charlotte, Charlottesville, Chicago, Grand Rapids, Houston, …Age 18+ - Long-term safety study of aficamten in adults with hypertrophic cardiomyopathy
Studies long-term safety of aficamten in adults with a heart thickening disease.
Anchorage, United StatesAlso Ann Arbor, Atlanta, Birmingham, Boston, Burlington, Charleston, Charlotte, Charlottesville, …Age 18 to 85 - Tests a gene therapy, RP-A501, in boys with Danon disease
Tests the gene therapy RP-A501 in male patients with Danon disease.
Boston, United StatesAlso La Jolla, PhiladelphiaAge 8+ - Gene Therapy LX2006 Tested in Friedreich Ataxia Heart Disease
Tests LX2006 gene therapy against usual care in people with Friedreich ataxia heart disease.
Tampa, United StatesAge 6+ - Switching from mavacamten to aficamten in obstructive hypertrophic cardiomyopathy
Tests aficamten as a switch from mavacamten in adults with obstructive hypertrophic cardiomyopathy.
Kansas City, United StatesAlso PortlandAge 18 to 90 - Tests TN-201 gene therapy in adults with inherited heart thickening disease
Tests TN-201 gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 gene changes in adults.
Atlanta, United StatesAlso Boston, Cincinnati, Cleveland, Houston, La Jolla, Philadelphia, Portland, Rochester, …Age 18 to 75 - Follow-up heart imaging in people with hypertrophic cardiomyopathy
Re-scans previous participants with thickened heart muscle to study heart-risk markers.
Ann Arbor, United StatesAlso Boston, Charlottesville, Cleveland, Medford, RochesterAge 18 to 65 - Follows adults with thickened heart muscle and mavacamten or other treatments
Observes people with blocked-flow heart thickening who take mavacamten or other medicines.
Anchorage, United StatesAlso Aurora, Baltimore, Bethlehem, Boston, Charlotte, Charlottesville, Chicago, Cincinnati, …Age 18+ - Following Heart Conditions Over Time Using Digital Monitoring Devices
Observes how long-term heart and blood pressure conditions change, using digital monitoring devices.
Chicago, United StatesAge 18+ - Imaging study to find causes of heart muscle disease in Bronx patients
Uses heart imaging to study heart muscle disease in adults from diverse groups.
The Bronx, United StatesAge 18+ - Studying Genetic Causes of Heart Muscle Disease in Children
Collects genetic information from children with heart muscle disease and their families.
Indianapolis, United States - Checking spine tissue from older adults for a heart protein buildup
Checks spinal tissue from adults 50 and older for signs of heart amyloidosis.
Beverly Hills, United StatesAlso Boston, Cleveland, New York, RochesterAge 50+ - Creating Stem Cell Models of Inherited Heart Rhythm Disorders
Collects blood or skin samples from patients with inherited heart rhythm disorders and healthy volunteers.
Baltimore, United StatesAge 18 to 85 - Tests moderate exercise training in people with hypertrophic cardiomyopathy
Tests a moderate exercise program against usual activity in adults with hypertrophic cardiomyopathy.
San Francisco, United StatesAge 18 to 80 - Tracks pregnancy and infant outcomes after mavacamten exposure in pregnant or breastfeeding people
Observes pregnancy and infant outcomes in people taking mavacamten during pregnancy or breastfeeding.
Wilmington, United StatesAge 15+ - Testing AI language models to help general cardiologists care for heart muscle disease
Tests AI language models helping general cardiologists manage hypertrophic cardiomyopathy cases.
Palo Alto, United StatesAge 18+ - Tracks how patients with obstructive hypertrophic cardiomyopathy feel on mavacamten
Follows adults with a heart thickening condition who take mavacamten in everyday care.
Boston, United StatesAge 18+
Where treatment stands
There is usually no cure, but treatment can control the symptoms and help prevent problems caused by the disease.
Aficamten, on the EU list for this disease, got its first EU approval in February 2026.
Approved: 4
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 4
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 3
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The trials: ClinicalTrials.gov and the EU trials register, as copied into our trial database, checked on 12 November 2026. Every treatment in trials links to its own trial records; the texts are written by AI from them and checked against them by a second AI. People have not reviewed them yet. Placebo, standard medicines used for comparison and procedures are left out.
Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 7 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for hypertrophic cardiomyopathy. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.
Support organisations
Patient organisations and helplines in United States, for you and your family.
Hypertrophic cardiomyopathy organisations in United States
- Children's Cardiomyopathy Foundation (CCF)
US charity for families of children with cardiomyopathy, offering resources, an online community, specialty-center guidance, webinars and research updates.
- Hypertrophic Cardiomyopathy Association
US nonprofit providing support, advocacy and education for people living with hypertrophic cardiomyopathy (HCM) and their families.
General support in United States
- 988 Suicide & Crisis Lifeline
US national 24/7 free and confidential lifeline for anyone in suicidal crisis or emotional distress, reachable by calling or texting 988 or by chat.
- MedlinePlus
Free, easy-to-read health information service of the US National Library of Medicine (NIH) on diseases, conditions, drugs and wellness.
International organisations
Offer tissue or data
There are three ways to help research move faster.
Treatments approved outside the EU
We found no medicine for Hypertrophic cardiomyopathy approved in the US or Japan that is not approved in the EU. These are the ones approved in the EU.
Checked on 11 Nov 2026 in the official lists of the US (FDA), Japan (PMDA, approvals since April 2004) and the EU (EMA).
Your health insurer may pay part of the cost, sometimes all of it. This depends on your insurer, your plan and the country, so always ask your insurer before you go. For planned care in the EU, the EEA and Switzerland, ask about form S2.
“Miracle cure” fact checker
Social media spreads misinformation. Paste what you read here, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
- Omega-3 fatty acids (fish oil) & Hypertrophic cardiomyopathy
- Curcumin (turmeric) & Hypertrophic cardiomyopathy
- Stem cell treatment & Hypertrophic cardiomyopathy
- CBD (cannabidiol) & Hypertrophic cardiomyopathy
About Hypertrophic cardiomyopathy
A heart muscle condition, usually passed down in families, in which the walls of the heart become thick.1 Some people have no symptoms; others get chest pain, breathlessness, dizziness or fainting, especially during exercise.1 There is usually no cure, but medicines, procedures and devices can control the symptoms and prevent problems.2 It affects about 1 in 500 people, and for most it does not change daily life.2
What is it?
In hypertrophic cardiomyopathy (HCM), the heart muscle cells grow larger and the walls of the heart thicken, sometimes only in one part.2,1 The chambers inside become smaller and hold less blood, the walls can stiffen, and sometimes the thick muscle blocks blood leaving the heart.2,1
It is thought to affect about 1 in 500 people and is seen at all ages.2,1 Younger people tend to have a more severe form.1 Most people inherit it from a parent: it comes from changes in the genes that control how the heart muscle grows.2,1
The first signs
Some people have no symptoms and may first find out at a routine medical exam.1
- chest pain;1
- shortness of breath when active or lying down;1
- dizziness, light-headedness or fainting, especially during exercise;1
- a pounding or fluttering heartbeat (palpitations);1
- tiredness.1
In some young adults, the first sign is a sudden collapse, which can be fatal.1
How doctors find out
The doctor listens to your heart, where a murmur may be heard.1 Tests can include a heart trace (ECG), an ultrasound scan of the heart (echocardiogram), an MRI scan, a heart rhythm monitor worn for 24 hours or longer, and an exercise test.1 Specialists may draw a detailed family tree.2 If an inherited type is found, a genetic test can look for the faulty gene, and close relatives can then be checked, so that they can be watched and treated early if they have it.2,1
Current treatment
Beta blockers or calcium channel blockers ease symptoms, other medicines treat rhythm problems, and some people need an implanted defibrillator (ICD), a myectomy or alcohol septal ablation.Source: MedlinePlus
Will it get worse?
For most people it does not affect daily life, and some live a normal lifespan without symptoms.2,1 In others it gets worse, slowly or quickly.1 It can lead to atrial fibrillation or a leaky heart valve, can worsen symptoms of heart failure, and raises the risk of sudden death, even at a young age.2,1 It is the most common cause of sudden unexpected death in children and young athletes, and almost half of deaths from HCM happen during or just after physical activity.2,1 If it is severe, you need regular checks.2
Medicines: what helps, and what to watch for
Not everyone needs treatment.2 Beta blockers and calcium channel blockers can ease chest pain and breathlessness during exercise.1 Other medicines treat heart rhythm problems, extra fluid and blood clots. If you have atrial fibrillation, you may be given blood thinners to lower the risk of blood clots.2,1 For adults with symptoms from thick heart muscle that blocks blood flow (obstructive hypertrophic cardiomyopathy), the medicine mavacamten works so that the heart does not squeeze so hard.3
Good to know about mavacamten:
Exercise and healthy habits help too
Procedures and surgery, for some people
If the thick muscle badly blocks blood leaving the heart, a surgeon can remove part of it (septal myectomy), sometimes repairing a leaky valve at the same time.2,1 Another option is an alcohol injection into the artery that feeds the thick part, which shrinks it; many people improve a lot.1,2 A pacemaker, or an implanted defibrillator (ICD) to stop dangerous heart rhythms, may be fitted; an ICD can be offered to people at high risk even before any rhythm problem.1,2 Ablation treats the tissue causing rhythm problems.2 A heart transplant is a last resort.2
Is there a cure?
There is usually no cure.2,3 Treatment controls the symptoms and helps prevent complications.2
Sources
Written in plain words by Frontlight from these pages: